Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - December 9, 2024) - Kincora Copper Limited (TSXV: KCC) (the "Company", "Kincora") is pleased to announce the results of voting at its Annual General and Special Meeting ("AGM" or the "Meeting") on December 9th, 2024 at 4pm PST held by hybrid meeting with webcast from Vancouver, Canada.All matters submitted to shareholders for approval as set out in the Company's Notice of Meeting and Information Circular, dated November 8th, 2024, were approved by the requisite majority of votes cast at the Meeting with 23.53% of shareholder proxies returned.Details of the resolutions are provided below as well as an update that was presented to shareholders at the Meeting.This announcement has been authorised for release by the Board of Kincora Copper Limited.By order of the Board of Directors:Cameron McRae, Chairmanenquiries@kincoracopper.com or +1 604 283 1722Kincora Copper Limited (ARBN 645 457 763)Executive office CanadaSubsidiary office Australia 400 - 837 West Hastings StreetVista AustraliaVancouver, BC V6C 3N6, CanadaLevel 4, 100 Albert RoadTel: 1.604.283.1722South Melbourne, Victoria 3205Fax: 1.888.241.5996Tel: +613 9692 7222 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.AGM detailsAudited Annual Report Shareholders received and considered the Financial Statements for the financial year ended December 31, 2023 and the report of the auditor thereon.Number of Directors | 99.89% ForShareholders approved retaining the number of directors at five (5).Election of Directors Shareholders voted in favour of Kincora's management's nominees to the board of directors: Jonathan (Sam) Spring (99.87% For), John Holliday (99.87% For), Luke Murray (99.81% For), Cameron McRae (91.71% For) and Jeremy Robinson (99.85% For).Auditor Appointed | 100.00% ForManning Elliot LLP was appointed Auditor of the Company to hold office until the next AGM or until its successor is duly appointed, and the directors were authorized to fix the Auditor's remuneration.Approval of Issue of Tranche 2 Placement Shares | 98.83% ForShareholders passed an ordinary resolution to ratify the issuance prior placement shares as described in the Information Circular.Approval of Issuance Placement Option | 98.75% ForShareholders passed an ordinary resolution to ratify the issuance of placement options relating to prior placement shares as described in the Information Circular.Ratification of Prior Issuance of Placement Shares | 99.58% ForShareholders passed an ordinary resolution to ratify the issuance prior placement shares as described in the Information Circular.Share Capacity | 99.50% ForShareholders passed a special resolution re-approving the capacity to issuance up to an additional 10% capital over a 12 month period pursuant to ASX Listing Rule 7.1A as described in the Information Circular.Equity Incentive Plan (EIP) | 99.74% ForShareholders passed an ordinary resolution re-approving of the existing EIP as amended as described in the Information Circular.Shares for Services Agreement | 90.76% ForShareholders passed an ordinary resolution re-approving of the existing shares for services agreements as described in the Information Circular.Ratification of Prior Issuance of Options pursuit to EIP | 90.84% ForShareholders passed an ordinary resolution to ratify the issuance prior options pursuit to the existing EIP as described in the Information Circular.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233137 Copyright 2024 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, Dec 9, 2024 - (ACN Newswire via SeaPRwire.com) - On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies.Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits.According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand.The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China.With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS's commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.References:1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-001644. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htmCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

- BIP Asia Forum welcomed over 3,000 participants- E-Day attracted around 11,800 visits, facilitated over 230 business matching meetings and created business opportunities for participants- IP financing as a growth engine should not be overlooked according to an IP valuation expert at BIP Asia Forum. IP valuers are subjected to professional scrutiny and need to do an inordinate amount of background research in order to put the information into a sensible IP context- Connecting start-ups from across the globe, E-Day reflects Hong Kong's growing role as a global innovation hub. Over the years, Hong Kong has introduced significant policies to support innovation and technology, especially with more proactive measures to drive university research translation and industry-academia collaborationHONG KONG, Dec 8, 2024 - (ACN Newswire via SeaPRwire.com) – The two-day Business of IP Asia Forum (BIP Asia Forum), jointly organised by the Hong Kong Special Administrative Region Government (HKSAR Government) and Hong Kong Trade Development Council (HKTDC), and held concurrently with Entrepreneur Day (E-Day), hosted by the HKTDC, concluded successfully on Friday 6 December. The two events brought together more than 160 intellectual property (IP) experts and business leaders from around the world to explore the potential of IP, promote business innovation and growth, and drive high-quality economic development. Taking place on 5 and 6 December, BIP Asia Forum and E-Day reinforced Hong Kong’s position as a leading regional IP trading centre and an international innovation and technology hub.The two events featured a mix of forums, exhibitions, competitions, workshops, and business matching meetings. More than 400 exhibitors from various sectors, including IP and innovation and technology, participated in the two events to capture business opportunities and gain insights into the latest IP and innovation trends.This year, BIP Asia Forum welcomed over 3,000 participants, while E-Day attracted around 11,800 visits and facilitated over 230 business matching meetings, creating business opportunities and fostering expansion for participants.This year’s BIP Asia Forum, themed “Reimagining IP for Impact and Growth”, featured a Policy Dialogue on the opening day, where international IP experts and representatives from multinational organisations shared insights on the flourishing and newest developments in the IP world.Cultural and creative IP unleashes huge potentialThe HKSAR’s 2024 Policy Address emphasised strengthening Hong Kong’s position as an IP trading centre, promoting cross-sectoral exchange, and encouraging more local and international cultural and creative products to be registered on the Asia IP Exchange Portal. The HKSAR Government also recently published the Blueprint for Arts and Culture and Creative Industries Development, highlighting the significant potential of cultural and creative IP.The HKTDC continues to be active in promoting cultural and creative IP resources from Hong Kong and overseas to facilitate industry exchange and collaboration. In addition to the annual BIP Asia Forum, the HKTDC leverages physical trading platforms such as the Hong Kong International Licensing Show and the Hong Kong International Film & TV Market to actively promote the development and trading of cultural and creative products, inviting various IP experts to share practical case studies and opportunities.Cultural and creative industries encompass various sectors, including film and television entertainment and music and arts. Jake Hwang, Chief Manager, Story IP Business at Kakao Entertainment Corp, renowned for his experience with popular web novels and comics IP projects such as What’s Wrong with Secretary Kim, Business Proposal, and Run On, shared insights on IP related to popular Korean dramas, webcomics, and web novels at the forum. He said: “In terms of creating original IPs and where we invest our money, we don’t see things in short-term income. We are trying to see things on a more long-term basis, because we don’t know which IPs will be successful. But we keep trying to produce new IPs every day. We also try to meet with global partners as much as possible. It could be physical productions, over-the-top platforms, or independent producers, just to open potential and discuss freely.”In today’s competitive business landscape, leveraging IP has become essential for driving innovation, building brand value, and creating new revenue streams. Many international brand leaders agree that IP plays a crucial role in developing strategies for sustainable growth and expanding into new areas. Dr Na Wei, Senior Director of IP Licensing at Xiaomi, believes in the importance of collaboration between different IP owners. “One smartphone may contain more than 200,000 patents. It’s not something that one company can do on its own, so that’s why collaboration is very necessary. We need to work with many other patent owners on acquiring or securing their licenses, and we also license our own patents to them. It’s in that way that these kind of high-density patent products can be made possible.Among the various areas of IP, one area with growth potential is IP financing, where businesses can use their intangible assets as collateral to secure funding without diluting equity. This means that an IP portfolio facilitates access to capital but also enhances a company’s valuation significantly. Martin Brassell, Co-founder and CEO at Inngot Limited said: “As valuers, we have to exercise our professional judgement, subject the inputs that we’re given to professional scrutiny, and do an inordinate amount of background research in order to put the information we’re being given into a sensible, commercial, and, if necessary, IP landscape context. That’s really where the hard yards are.”This year’s Innovation & IP Market, themed “Smart City Innovation”, showcased over 20 innovative projects in areas such as smart city technology, digital business, smart living, artificial intelligence (AI) and robotics, and transportation. Xu Song, Deputy Director, Science & Technology Innovation Division of the Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone of Shenzhen said: “The Business of IP Asia Forum provided an excellent platform for exploring business opportunities and networking. The Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone of Shenzhen gathered enterprises and institutions in the field of intellectual property and joined the forum. They received enquiries from over 40 renowned IP organisation and technology companies from various countries and regions regarding policies and measures for establishing operations in Qianhai. This helps enterprises in both ‘going global’ and ‘attracting foreign investment’."E-Day promotes exchange and uncovers new opportunitiesThe HKTDC E-Day also concluded on Friday. Themed “Where Start-up Dreams Take Flight”, this year’s E-Day showcased over 340 start-ups, invention projects, and support services from 13 countries and regions, and invited more than 60 industry leaders to participate in business matching meetings and networking events.Hong Kong start-up Lacess Limited participated in E-Day for the first-time, showcasing sustainable footwear made from upcycled farm waste, factory waste, recycled plastic, and other innovative materials. Natalie Chow, CEO & Co-founder of Lacess Limited said: “As a start-up, we know the power of making connections to drive growth. Entrepreneur Day was an incredible opportunity to meet like-minded innovators, exchange ideas, and explore collaborations that could help us expand into new markets. It’s been inspiring to see how global businesses can come together to create meaningful change.The Thailand pavilion, organised by the Department of International Trade Promotion under the Ministry of Commerce of Thailand, participated in E-Day for the first time, showcasing 10 key start-ups from Thailand. Pannakarn Jiamsuchon, Thai Trade Commissioner & Consul (Commercial) said: “HKTDC’s E-Day provided a perfect platform for Thailand to shine. Our participation at E-day not only promoted the Thai start-up sector but also drew global investors into the market, creating a win-win situation for the international business community.”The Australian pavilion, led by Investment New South Wales (NSW), took part in E-Day for the second consecutive year, and showcased nine start-ups specialising in health tech, green tech, smart city solutions and other related technologies. A representative from the Australian pavilion said they wanted to take advantage of E-Day to introduce New South Wales’ start-ups to overseas markets.Start-up Express International leads top start-ups to explore Greater Bay Area opportunitiesNow in its third edition, Start-up Express International continues to support global start-ups in establishing a presence in Hong Kong and expanding into regional markets. The programme is supported by global partners worldwide, and 10 winning global start-ups were selected last month. The winning start-ups attended the “Start-up Express International – Meet the Global Winners” session during E-Day to share their entrepreneurial experiences and network with each other.Jimmy Ng, Investment Director at Gobi Partners, said: “It’s amazing to see Start-up Express International connecting top start-ups from across the globe further reflecting Hong Kong's growing role as a global innovation hub. Over the years, Hong Kong has introduced significant policies to support innovation and technology, especially with more proactive measures to drive university research translation and industry-academia collaboration. These efforts, combined with initiatives to boost start-up funding and private investment, are creating a strong ecosystem that empowers entrepreneurs to turn their ideas into impactful businesses.”[Replay of BIP Asia Forum event, including highlights of the exhibition and forums, will be available from 7 December 2024 to 6 January 2025. Replay of E-Day event will be uploaded after 7 January 2025.]BIP Asia Forum website: https://bipasia.hktdc.com/en/E-Day website: https://eday.hktdc.com/enStart-up Express International website: https://portal.hktdc.com/startupexpress/en/s/start-up-express-internationalPhoto Download: https://bit.ly/3ZDjnnzIP valuation and financing experts gathered experts to discuss current trends, share best practices and shed light on the potential of bringing IP financing to the mainstream.The Innovation & IP Market, themed “Smart City Innovation”, showcased over 20 innovative projects in areas such as smart city technologies, digital business, smart living, artificial intelligence and robotics, and transportationThe HKTDC E-Day, themed ‘Where Start-up Dreams Take Flight’, attracted around 11,800 visitsStart-ups funded under the Funding Scheme for Youth Entrepreneurship in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA), supported by the Home and Youth Affairs Bureau, also participated, sharing their experiences and success stories of starting businesses in the GBAThe Thailand pavilion, organised by the Department of International Trade Promotion under Ministry of Commerce of Thailand, participated in E-Day for the first time, showcasing 10 key start-ups from ThailandMedia enquiriesFor enquiries, please contact:Burson:Wing Chan Tel: (852) 9518 4326 Email: wing.chan@hillandknowlton.comRachel Zhu Tel: (852) 6816 5846 Email: rachel.zhu@hillandknowlton.comHKTDC’s Communication & Public Affairs Department:Katy Wong Tel: (852) 2584 4524 Email: katy.ky.wong@hktdc.orgJane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.orgHKTDC Media Room: http://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong ’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly SMEs, in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. Copyright 2024 ACN Newswire via SeaPRwire.com.